 Fibrin Fibrinogen Degradation Products
"Fibrin Fibrinogen Degradation Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis.
| Descriptor ID |
D005338
|
| MeSH Number(s) |
D12.776.124.270.300 D12.776.811.300.290
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fibrin Fibrinogen Degradation Products".
Below are MeSH descriptors whose meaning is more specific than "Fibrin Fibrinogen Degradation Products".
This graph shows the total number of publications written about "Fibrin Fibrinogen Degradation Products" by people in this website by year, and whether "Fibrin Fibrinogen Degradation Products" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 2 | 0 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 1 | 2 | | 2011 | 0 | 3 | 3 | | 2012 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 2 | 3 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 2 | 3 | | 2020 | 1 | 1 | 2 | | 2021 | 0 | 2 | 2 | | 2022 | 1 | 0 | 1 | | 2023 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Fibrin Fibrinogen Degradation Products" by people in Profiles.
-
Park AJ, Garcia VP, Greiner JJ, Berry AR, Cardenas HL, Wegerson KN, Stauffer B, DeSouza CA. Development of a Hypercoagulable-Hypofibrinolytic State Early After Spinal Cord Injury. Arch Phys Med Rehabil. 2024 05; 105(5):843-849.
-
Hess CN, Hsia J, Carroll IA, Nehler MR, Ruf W, Morrow DA, Nicolau JC, Berwanger O, Szarek M, Capell WH, Johri S, Pursley MS, Gupta R, Meehan PS, Franchi F, Effron MB, Marshall D, Graybill CA, Huebler SP, Keuer T, Bristow MR, Bonaca MP. Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arterioscler Thromb Vasc Biol. 2023 08; 43(8):1572-1582.
-
Gilens JF, Khodaee M. Does a negative d-dimer test result rule out deep-vein thrombosis? Can Fam Physician. 2022 03; 68(3):195.
-
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G, Lund JM, Tafur A, Lewis PA, Cohoon KP, Rahman H, Sison CP, Lesser ML, Ochani K, Agrawal N, Hsia J, Anderson VE, Bonaca M, Halperin JL, Weitz JI. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med. 2021 12 01; 181(12):1612-1620.
-
Thibord F, Song C, Pattee J, Rodriguez BAT, Chen MH, O'Donnell CJ, Kleber ME, Delgado GE, Guo X, Yao J, Taylor KD, Ozel AB, Brody JA, McKnight B, Gyorgy B, Simonsick E, Leonard HL, Carrasquilla GD, Guindo-Martinez M, Silveira A, Temprano-Sagrera G, Yanek LR, Becker DM, Mathias RA, Becker LC, Raffield LM, Kilpel?inen TO, Grarup N, Pedersen O, Hansen T, Linneberg A, Hamsten A, Watkins H, Sabater-Lleal M, Nalls MA, Tr?gou?t DA, Morange PE, Psaty BM, Tracy RP, Smith NL, Desch KC, Cushman M, Rotter JI, de Vries PS, Pankratz ND, Folsom AR, Morrison AC, M?rz W, Tang W, Johnson AD. FGL1 as a modulator of plasma D-dimer levels: Exome-wide marker analysis of plasma tPA, PAI-1, and D-dimer. J Thromb Haemost. 2021 08; 19(8):2019-2028.
-
Narang J, Nowacki AS, Seballos SS, Wang PR, Mace SE. D-dimer can help differentiate suspected pulmonary embolism patients that require anti-coagulation. Am J Emerg Med. 2021 07; 45:361-367.
-
Wright FL, Vogler TO, Moore EE, Moore HB, Wohlauer MV, Urban S, Nydam TL, Moore PK, McIntyre RC. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection. J Am Coll Surg. 2020 08; 231(2):193-203.e1.
-
Siedner MJ, Bwana MB, Asiimwe S, Musinguzi N, Castillo-Mancilla J, Amanyire G, Tracy RP, Bangsberg DR, Orrell C, Haberer JE. Inflammatory biomarkers prior to antiretroviral therapy as prognostic markers of 12-month mortality in South Africa and Uganda. AIDS. 2019 11 01; 33(13):2043-2048.
-
Moore HB, Moore BA, Sauaia A, Moore EE. Clinical relevance and practical assessment of fibrinolysis shutdown. ANZ J Surg. 2020 04; 90(4):413-414.
-
Siedner MJ, Bwana MB, Asiimwe S, Amanyire G, Musinguzi N, Castillo-Mancilla J, Tracy RP, Katz IT, Bangsberg DR, Hunt PW, Orrell C, Haberer JE. Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study. J Infect Dis. 2019 08 30; 220(7):1172-1177.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|